Method of treating fungal infection

Patent metadata

Field	Value
Publication number	US-10806776-B2
Application number	US-201815969169-A
Country	US
Kind code	B2
Filing date	May 2, 2018
Priority date	Mar 12, 2013
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

A vaccine comprising Calnexin fragment and a method of using the vaccine to immunize a patient against fungi are disclosed. The Calnexin fragment may be either a full-length native version or a functionally equivalent version of full-length Calnexin.

First claim

We claim:

1. A vaccine to immunize a patient against fungi, wherein the vaccine comprises a therapeutically effective amount of an immunogenic Calnexin peptide consisting of a sequence of 13 amino acids with 1, 2, or 3 amino acid substitutions relative to SEQ ID NO:1 and at least one of a stabilizer, a buffer, or a therapeutically effective amount of an adjuvant.

2. The vaccine of claim 1 , wherein the Calnexin peptide consists of a sequence selected from the group consisting of SEQ ID NOs: 10, 12, 15, 20, 25, 29, and 30.

3. A method of protecting a patient subject from fungal infection comprising administering a therapeutically effective amount of the vaccine of claim 1 to the subject, wherein the subject is protected from fungal infection.

4. The method of claim 3 , wherein the fungi are either dimorphic fungi or non-dimorphic fungi.

5. The method of claim 4 , wherein the dimorphic fungi are selected from a group consisting of Histoplasma, Coccidiodes, Paracoccidiodes, Penicillium, Blastomyces , and Sporothrix.

6. The method of claim 4 , wherein the non-dimorphic fungi are selected from a group consisting of Aspergillus, Pneumocystis, Magnaportha, Exophiala, Neuroaspora, Cryptococcus, Schizophyllum , and Candida.

7. The method of claim 3 , wherein the Calnexin peptide of the vaccine is expressed and isolated from E. Coli.

8. A vaccine to immunize a patient against a fungi comprising recombinant full-length Calnexin having a sequence selected from the group consisting of SEQ ID NO:35 and SEQ ID NO:36 and at least one of a stabilizer, a buffer, or a therapeutically effective amount of an adjuvant.

9. The vaccine of claim 8 , wherein the recombinant full-length Calnexin is not glycosylated.

10. The vaccine of claim 1 , wherein the vaccine additionally comprises complete Freund's adjuvant and heat killed C. albicans.

11. A method of protecting a patient from fungal infection comprising administering a therapeutically effective amount of the vaccine of claim 8 to a subject, wherein the subject is protected from fungal infection.

12. The method of claim 11 , wherein the fungi are either dimorphic fungi or non-dimorphic fungi.

13. The method of claim 12 , wherein the dimorphic fungi are selected from a group consisting of Histoplasma, Coccidiodes, Paracoccidiodes, Penicillium, Blastomyces , and Sporothrix.

14. The method of claim 12 , wherein the non-dimorphic fungi are selected from a group consisting of Aspergillus, Pneumocystis, Magnaportha, Exophiala, Neuroaspora, Cryptococcus, Schizophyllum , and Candida.

15. The method of claim 11 , wherein the recombinant full length Calnexin of the vaccine is expressed and isolated from E. Coli.

Assignees

• Wisconsin Alumni Res Found

Inventors

• Klein Bruce Steven
• Brandhorst Theodore Tristan
• Sullivan Thomas
• Wuethrich Marcel

Classifications

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title

• A61K39/0002 Primary

  Fungal antigens, e.g. Trichophyton, Aspergillus, Candida · CPC title

• C07K14/37

  from fungi · CPC title

• A61K2039/55566

  Emulsions, e.g. Freund's adjuvant, MF59 · CPC title

• C07K16/14

  against material from fungi, algea or lichens · CPC title